Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 9/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | F11 | P03951 | 4/20 | 0.41 |
| ▸ | F7 | P08709 | 4/20 | 0.41 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.40 |
| ▸ | ICMT | O60725 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | BAD | Q92934 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4815653 | 0.91 | SLC22A12 (0.41) | F10SLC22A12F11F7 | |
| SCHEMBL4807618 | 0.81 | ALDH1A1 (0.41) | F10SLC22A12F11F7LMNA | |
| SCHEMBL4816668 | 0.80 | ADRA1D (0.39) | HDAC1HDAC8HDAC6SERPINE1ICMT | |
| SCHEMBL4809426 | 0.77 | PLA2G2A (0.52) | HDAC1HDAC6F10F7ICMT | |
| SCHEMBL5899841 | 0.74 | HDAC1 (0.43) | HDAC1HDAC8HDAC6F10F7 | |
| SCHEMBL12850648 | 0.72 | HDAC6 (0.74) | HDAC1HDAC8HDAC6LMNAALDH1A1 | |
| SCHEMBL4656156 | 0.72 | PLA2G2A (0.51) | F10F7ICMTLMNAALDH1A1 | |
| SCHEMBL4814925 | 0.71 | PLA2G4A (0.40) | F10SLC22A12F11F7LMNA | |
| SCHEMBL5150813 | 0.71 | SLC22A12 (0.39) | F10SLC22A12F7 | |
| SCHEMBL4812278 | 0.71 | PLA2G2A (0.44) | HDAC1HDAC6F10F7ICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417063-B2 | Bicyclic heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | claimed |
| US-20050228000-A1 | of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent | BRISTOL-MYERS SQUIBB COMPANY | 2005-10-13 | — | — | US | claimed |
| US-7417063-B2 | Bicyclic heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20050228000-A1 | of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent | BRISTOL-MYERS SQUIBB COMPANY | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228000-A1 | of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent | F12, F11, F2 | HDAC1 1133/4885HDAC8 868/4885HDAC6 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.